|
|
|
|
|
非在研适应症- |
最高研发阶段早期临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
100 项与 Kariya Pharmaceuticals ApS 相关的临床结果
0 项与 Kariya Pharmaceuticals ApS 相关的专利(医药)
100 项与 Kariya Pharmaceuticals ApS 相关的药物交易
100 项与 Kariya Pharmaceuticals ApS 相关的转化医学